key: cord-0286009-8mqe28g5 authors: Kelley, K.; Kelley, M.; Kelley, S. C.; Sakara, A. A.; Ramirez, M. A. title: AI/ML Models to Aid in the Diagnosis of COVID-19 Illness from Forced Cough Vocalizations: Good Machine Learning Practice and Good Clinical Practices from Concept to Consumer for AI/ML Software Devices date: 2021-11-15 journal: nan DOI: 10.1101/2021.11.13.21266289 sha: 1e05e1c5807478be790d9fe1199cd4c8ed42d185 doc_id: 286009 cord_uid: 8mqe28g5 From a comprehensive and systematic search of the relevant literature on signal data signature (SDS)-based artificial intelligence/machine learning (AI/ML) systems designed to aid in the diagnosis of COVID-19 illness, we identified the highest quality articles with statistically significant data sets for a head-to-head comparison to our own model in development. Further comparisons were made to the recently released "Good Machine Learning Practice (GMLP) for Medical Device Development: Guiding Principles" and, in conclusions, we proposed supplemental principles aimed at bringing AI/ML technologies in closer alignment GMLP and Good Clinical Practices (GCP). Artificial intelligence and machine learning (AI/ML) technologies have the potential to augment and democratize health care by providing analysis and insights into the vast amount of healthrelated data collected pertaining to individuals, as well as their communities. The promise of AI/ML solutions to realize these goals, however, has been hampered by the failure of both Software as Medical Device (SaMD) and Software in Medical Device (SiMD) manufacturers to employ medical device industry standards for design, documentation, testing, manufacturing and deployment across the Total Product Life Cycle (TPLC). We prospectively planned a PRISMA 2020 systematic review of the relevant literature to demonstrate reproducibility of the published models by building each COVID-19 diagnostic software system for which sufficient details were reported and to conduct head-to-head evaluations both across the completed models and in comparison, to our own AI/ML system. As a secondary objective, our intent was to determine a literature-derived performance goal (PG) for the completed models for comparison to our device with the same intended use. Poor data quality leading to poorly trained AI/ML models that cannot perform in a clinical setting has been described extensively in the literature [1] [2] [3] [4] . Inadequate sample sizes for training, validation, and testing are often secondary to the lack of availability of datasets that results in a lack of statistical significance and subsequent rejection by informed clinicians. Furthermore, authors within the current literature have not utilized a prospective plan for the total product life cycle (TPLC) of their device -a necessity for regulatory approval and deployment in the clinical world -promoting a lack of prospective objectives for intended use. The literature also demonstrated a lack of ability of the current models to meet minimum standards set forth by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) for safety and performance. Along with the risks of bias stemming from socioeconomic disparities in data collections, each of these gaps echo statements made in current editorials presenting the challenges of advancing AI/ML technology to aid in the diagnosis of COVID-19 [1] [4] . On 29 October 2021, FDA, CanadaHealth and the Medicines and Healthcare products Regulatory Agency (MHRA) jointly developed and published 10 guiding principles for "Good Machine Learning Practice (GMLP) for Medical Device Development: Guiding Principles," for the TPLC of SaMDs and SiMDs [5] . The GMLP is a companion to the 13 guiding principles for Good Clinical Practices (GCP) for medical device clinical trials published by the International Conference on Harmonization (ICH) and endorsed by FDA in 1997 [6] [7] . With the GCP, standards were set for the design, conduct, and reporting of clinical trials and is key to bringing new medical devices to market. This article will discuss how these principles can be applied to the TPLC to align AI/ML development with clinical trial design and endpoints. Prior reporting of our methodology and results were detailed in K. Kelley et al. [K. Kelley et. al. 2021 -Manuscript Submitted for Publication] and have been reproduced below in part for ease of reference. As previously described by our team, we conducted systematic searches of the relevant literature on 12 October 2021 and updated on 7 November 2021, for the purpose of presenting a comparative evaluation of AI/ML systems designed to aid in the diagnosis of COVID-19 from FCV. Searches of the peer-reviewed literature were prioritized but, given the collaborative "shareware" culture of the AI/ML and Data Science communities, pre-print servers were searched for possible contributions. EndNote 2020 was the designated reference manager and PubMed was searched via this software. Serial searches of "Any Field" in PubMed, "Full Text and Metadata" in the IEEE Xplore digital library of the Institute of Electrical and Electronics Engineers, (ieeexplore.ieee.org), "All Fields" in the arXiv open-access archive (arxiv.org), and "Full Text or Abstract or Title" in bioRxiv and medRxiv (medrxiv.org) were performed using the identical search terms as listed below: • covid and classifier • covid and neural network • covid and cough and artificial intelligence • covid and cough and AI • covid and cough and machine learning • covid and cough and ML • covid and cough and classifier • cough and neural network • forced cough vocalization The results from these serial searches were combined and systematically filtered to achieve a final article pool from which all references would be evaluated for contribution to the stated objectives. Following a basic PRISMA 2020 workflow, our search methodology is illustrated below in Figure 1 : From the final pool of 64 references, the remaining 33 peer-reviewed articles and 24 pre-print server records were read and evaluated in full across a multidisciplinary team of Data . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.13.21266289 doi: medRxiv preprint No single reference included sufficient details to build a complete model or system, rendering comparisons across models (including our own) unattainable. The primary objectives of the review, therefore, could not be met. Determination of a literature-derived Performance Goal (PG) was the secondary objective of the original review and is a familiar endpoint in regulatory pathways. None of the references met all inclusion criteria, however, rendering the secondary objective unattainable. Since the intended objectives of our original systematic review could not be met, we undertook to compare the two peer-reviewed articles [8] [9] that demonstrated statistically significance data sets consistent with the requirements for a regulatory pathway and to our model in development. These comparisons will be presented in relationship to two frameworks: the principles of the recently released GMLP and the predicate principles of the GCP for Medical Devices. The new proposed primary objective was to compare the two articles previously identified as having Level 2a design, Moderate Grade data, and a statistically significant test set size for headto-head comparison to each other and also to our model in development. 2) Clear, comprehensive documentation of software engineering practices used is key. 3) All data scientists trained in-house for biotechnical engineering certification. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The machine was tested against RT-PCR and information was obtained from subjects on symptomology. Model was tested against RT-PCR and information obtained from physicians on symptomatology. 1) Benchtop tested against RT-PCR and information obtained from physicians on symptomatology. 2) RT-PCR and Sanger sequencing for clinical trial testing to ensure true positive and negative. 9 Users are Provided Clear, Essential Information Once an AI/ML medical device is developed and ready for clinical testing, there are 13 Good Clinical Practice (GCP) principles that must be observed by international law. AI/ML is not universally accepted in healthcare and problems encountered along the way from inception to . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.13.21266289 doi: medRxiv preprint deployment of a diagnostic SaMD are varied and many. Changing the level of acceptance will require adherence to Good Clinical Practice. Our next objective was to compare the same two articles head-to-head with our model evaluating GCP. A detailed protocol was written prior to initiating the clinical trial . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 protocol A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB) / independent ethics committee (IEC) approval/favorable opinion. The clinical trial was approved by local IECs. The trial was approved by clinical by a national IRB and accepted by the local IRB. The medical care given to, and medical decisions made on behalf of subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The publication of GMLP that has followed the GCP for Medical Devices raises the bar for the scientific rigor of SiMD/SaMD development, the associated benchtop testing, and clinical trials. Collectively, these principles reinforce that prospective design applies not only to the design of the software but also the testing and, ultimately, the evidence-based clinical trial of the device. Our review of 57 articles and reports describing FCV-SDS based COVID-19 diagnostic software components and systems found that only 2 of the 57 articles could meet Level of Evidence, grade of data and statistical significance of testing criteria. When these 2 articles were evaluated against the principles for GMLP and GCP, only the article by Andreu-Perez et al. demonstrated a degree of compliance with the guidelines [8] . Our own experience, albeit pre-clinical trial, found that the GMLP and GCP guidelines are well aligned with good engineering practices and good evidence-based medicine research practices. We respectfully submit the following supplements to the GMLP and GCP to include preclinical . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 benchtop testing principles, techniques to ensure AI/ML model consistency and guidance for overcoming data borders: • Prior to Clinical Trial, investigational AI/ML software devices should be trained and validated using a reference dataset that is clinically relevant to the proposed clinical trial. Furthermore, the model should demonstrate successful benchtop testing using a testing dataset that is clinically relevant and with testing endpoints that are identical to prospectively designed clinical trial. This will promote adherence to two of the current GMLP principles -separation of training and test sets and providing for the highest quality of data. • The trained and validated AI/ML models used in pre-clinical trial benchtop testing and for clinical trials should be reproducible by independent researchers. This requires that the source code for the complete model, including post training transfer learning, is made available as part of peer-reviewed published reports to facilitate replication of the benchtop testing and/or clinical trials. The use of original source code and transfer learning ensures that the replicated tests and trials are using the identical AI/ML model, making direct comparisons possible. • Clinical trials that cross data borders and parallel AI/ML models operating in different data boundary regions should implement the same source code and transfer learning in all data regions. Additionally, if the clinical trial crosses data borders, parallel AI/ML models operating in different data boundary regions should synchronize transfer learning using federated data and swarm learning. This approach would respect applicable data boundaries, which is essential for international operations. Without these considerations, data borders will impose healthcare inequities and limit access. Adherence to GMLP and GCP by AI/ML SaMD and AI/ML SiMD developers will also serve to improve the confidence of healthcare providers and healthcare decision makers in these new and promising technologies. The newly released GMLP guidelines provide an ideal framework for AI/ML and SiMD/SaMD developers to guide their efforts throughout the TPLC, yielding more meaningful clinical outcomes. Data scientists, clinicians, and regulatory specialists must collaborate to ensure that good practices translate into a product that meets the needs of both healthcare providers and patients. Focusing on quality and incorporating regulatory guidance throughout the TPLC will allow AI/ML developers to bring a high-quality medical to market. GCP principles provide the guidance for clinical trials to be conducted ethically and scientifically with clear and detailed protocols. Care must be given by appropriately qualified personnel with adequate experience. Most importantly, documentation of adherence to these practices is key, with records easily accessible and retrievable for accurate reporting, verification and interpretation. In order to bring new AI/ML technology solutions to healthcare, developers must prospectively plan to use the GMLP and GCP principles from the beginning of the TPLC. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 COVID-19 detection from audio: seven grains of salt Challenges and Opportunities in Deploying COVID-19 Cough AI Systems COVID-19 and Computer Audition: An Overview on What Speech & SoundAnalysis Could Contribute in theSARS-CoV-2 Corona Crisis. Frontiers in Digital Health Is my cough COVID-19? softwaremedical-device-samd/good-machine-learning-practice-medical-device-developmentguiding-principles Food and Drug Administration Good Clinical Practices, 62 Fed A generic deep learning based cough analysis system from clinically validated samples for point-of-need covid-19 test and severity levels Exploring the Use of Artificial Intelligence Techniques to Detect the Presence of Coronavirus Covid-19 Through Speech and Voice Analysis Bibliography of the Systematic Review of the Literature Adans Can mHealth technology help mitigate the effects of the COVID-19 pandemic? Evaluating the COVID-19 Identification ResNet (CIdeR) on the INTERSPEECH COVID-19 from Audio Challenges Detection of COVID-19 in smartphone-based breathing recordings using CNN-BiLSTM: a pre-screening deep learning tool Deep Neural Networks for Identifying Cough Sounds A generic deep learning based cough analysis system from clinically validated samples for point-of-need covid-19 test and severity levels Cough against COVID: Evidence of COVID-19 signature in cough sounds Can machine learning be used to recognize and diagnose coughs? The voice of COVID-19: Acoustic correlates of infection in sustained vowels End-to-End AI-Based Point-of-Care Diagnosis System for Classifying Respiratory Illnesses and Early Detection of COVID-19: A Theoretical Framework Pre-processing and classification of cough sounds in noisy environment using SVM Exploring automatic diagnosis of COVID-19 from crowdsourced respiratory sound data The Levels of Evidence and Their Role in Evidence-Based Medicine. Plastic and reconstructive surgery DiCOVA-Net: Diagnosing COVID-19 using Acoustics based on Deep Residual Network for the DiCOVA Challenge Cough Detection Using Selected Informative Features from Audio Signals Multi-modal Point-of-Care Diagnostics for COVID-19 Based QUCoughScope: An Artificially Intelligent Mobile Application to Detect Asymptomatic COVID-19 Patients using Cough and Breathing Sounds An Ensemble-based Multi-Criteria Decision Making Method for COVID-19 Cough Classification Comparison of silence removal methods for the identification of audio cough events Novel coronavirus cough database: NoCoCoDa End-to-end convolutional neural network enables COVID-19 detection from breath and cough audio: a pilot study COVID-19 detection from audio: seven grains of salt An overview on audio, signal, speech, & language processing for covid-19 Audio, Speech, Language, & Signal Processing for COVID-19: A Comprehensive Overview Smartphone-based self-testing of COVID-19 using breathing sounds Deep-learning Based Approach to Identify Covid-19 Use of the GRADE approach in systematic reviews and guidelines CovidEnvelope: A Fast Automated Approach to Diagnose COVID-19 from Cough Signals Efficient k-NN Implementation for Real-Time Detection of Cough Events in Smartphones AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app A cognitive IoT-based framework for effective diagnosis of COVID-19 using multimodal data Challenges and Opportunities in Deploying COVID-19 Cough AI Systems Wavelet analysis of voluntary cough sound in patients with respiratory diseases COVID-19 artificial intelligence diagnosis using only cough recordings Automatic COVID-19 disease diagnosis using 1D convolutional neural network and augmentation with human respiratory sound based on parameters: cough, breath, and voice Cough detection using deep neural networks Diagnosis of COVID-19 and non-COVID-19 patients by classifying only a single cough sound Identifying COVID-19 by using spectral analysis of cough recordings: a distinctive classification study A comparative study of features for acoustic cough detection using deep architectures An ensemble learning approach to digital corona virus preliminary screening from cough sounds Robust Detection of Audio-Cough Events Using Local Hu Moments Effect of importance sampling on robust segmentation of audiocough events in noisy environments A machine hearing system for robust cough detection based on a high-level representation of band-specific audio features Robust Detection of COVID-19 in Cough Sounds DiCOVA Challenge: Dataset, task, and baseline system for COVID-19 diagnosis using acoustics Deming least square regressed feature selection and Gaussian neuro-fuzzy multi-layered data classifier for early COVID prediction Fruit-CoV: An Efficient Vision-based Framework for Speedy Detection and Diagnosis of SARS-CoV-2 Infections Through Recorded Cough Sounds The COUGHVID crowdsourcing dataset, a corpus for the study of large-scale cough analysis algorithms. Sci Data COVID-19 cough classification using machine learning and global smartphone recordings COVID-19 Detection in Cough Pay attention to the cough: Early diagnosis of COVID-19 using interpretable symptoms embeddings with cough sound signal processing SARS-CoV-2 detection from voice IATos: AI-powered pre-screening tool for COVID-19 from cough audio samples A framework for biomarkers of COVID-19 based on coordination of speech-production subsystems COVID-19 patient detection from telephone quality speech data Detecting COVID-19 from breathing and coughing sounds using deep neural networks COVID-19 and Computer Audition: An Overview on What Speech & SoundAnalysis Could Contribute in theSARS-CoV-2 Corona Crisis Grading quality of evidence and strength of recommendations for diagnostic tests and strategies Telehealthcare and Covid-19: A Noninvasive & Low Cost Invasive, Scalable and Multimodal Real-Time Smartphone Application for Early Diagnosis of SARS-CoV-2 Infection Impact of data-splits on generalization: Identifying COVID-19 from cough and context Coswara--A Database of Breathing, Cough, and Voice Sounds for COVID-19 Diagnosis Artificial intelligence enabled preliminary diagnosis for COVID-19 from voice cues and questionnaires Automated detection of COVID-19 cough Digital technology and COVID-19 Is my cough COVID-19? Exploring the Use of Artificial Intelligence Techniques to Detect the Presence of Coronavirus Covid-19 Through Speech and Voice Analysis Exploring Self-Supervised Representation Ensembles for COVID-19 Cough Classification